Tag: #Global Trends

Key Development In early September 2026, biopharmaceutical leaders Novartis AG (SIX: NOVN / NYSE: NVS) and Bristol Myers Squibb (NYSE:... Read more

Key Development On September 2, 2026, the Advanced Research Projects Agency for Health (ARPA-H), an agency operating within the U.S.... Read more

Key Development On September 2, 2026, Swiss multinational pharmaceutical leader Novartis AG (SIX: NOVN / NYSE: NVS) announced a structural... Read more

Key Development Treeline Biosciences has entered a clinical trial collaboration and drug-supply agreement with Roche to evaluate its investigational BCL6... Read more

Key Development On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque® (daraxonrasib), an oral small-molecule therapeutic... Read more

Key Development Teva Pharmaceutical Industries has reported positive Phase 2a topline results for TEV-408, an investigational human monoclonal antibody targeting... Read more

Key Development On August 28, 2026, the U.S. Food and Drug Administration (FDA) officially approved the supplemental Biologics License Application... Read more

Key Development On August 28, 2026, the U.S. Food and Drug Administration (FDA) officially granted marketing approval for Bixlenvo® (bictegravir... Read more

Key Development On August 27, 2026, the U.S. Food and Drug Administration (FDA) approved Bixlenvo® (bictegravir 75 mg / lenacapavir... Read more